文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year.

作者信息

Winslow Rebecca L, Milligan Iain D, Voysey Merryn, Luhn Kerstin, Shukarev Georgi, Douoguih Macaya, Snape Matthew D

机构信息

Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

出版信息

JAMA. 2017 Mar 14;317(10):1075-1077. doi: 10.1001/jama.2016.20644.

DOI:10.1001/jama.2016.20644
PMID:28291882
Abstract
摘要

相似文献

[1]
Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year.

JAMA. 2017-3-14

[2]
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.

JAMA. 2016-4-19

[3]
Adenovirus-vectored Ebola vaccines.

Expert Rev Vaccines. 2015

[4]
Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.

J Virol. 2006-3

[5]
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

Vaccine. 2010-10-27

[6]
Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine.

Mol Pharm. 2015-8-3

[7]
Immunology of protection from Ebola virus infection.

Sci Transl Med. 2015-5-6

[8]
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates.

Nat Med. 2011-8-21

[9]
Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.

J Infect Dis. 2015-10-1

[10]
Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.

J Infect Dis. 2011-11

引用本文的文献

[1]
A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose.

NPJ Vaccines. 2024-12-23

[2]
Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.

Nat Commun. 2024-9-3

[3]
Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.

Vaccines (Basel). 2024-5-4

[4]
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.

NPJ Vaccines. 2023-11-8

[5]
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans.

Front Immunol. 2023

[6]
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.

PLoS One. 2022

[7]
Ebola virus protein VP40 stimulates IL-12- and IL-18-dependent activation of human natural killer cells.

JCI Insight. 2022-8-22

[8]
NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans.

Vaccines (Basel). 2022-5-31

[9]
Viral vector vaccines.

Curr Opin Immunol. 2022-8

[10]
Vaccine Licensure in the Absence of Human Efficacy Data.

Vaccines (Basel). 2022-2-26

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索